Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
34.7M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
22.3M
-
Shares change
-
+532K
-
Total reported value, excl. options
-
$186M
-
Value change
-
+$4.17M
-
Put/Call ratio
-
0.09
-
Number of buys
-
41
-
Number of sells
-
-33
-
Price
-
$8.35
Significant Holders of IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) as of Q3 2023
93 filings reported holding IGMS - IGM Biosciences, Inc. - Common Stock, par value $0.01 per share as of Q3 2023.
IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.3M shares
of 34.7M outstanding shares and own 64.25% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (3.24M shares), BAKER BROS. ADVISORS LP (3.16M shares), Redmile Group, LLC (2.97M shares), Artal Group S.A. (2.52M shares), FMR LLC (2.14M shares), RA CAPITAL MANAGEMENT, L.P. (938K shares), VANGUARD GROUP INC (900K shares), BlackRock Inc. (871K shares), MILLENNIUM MANAGEMENT LLC (768K shares), and GREAT POINT PARTNERS LLC (615K shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.